ExpreS2ion Biotechnologies ApS was founded in 2010 as a spin out of the S2 expression platform from the Danish company Affitech A/S. The founders were scientists who had developed the platform as employees of initially Pharmexa A/S and following Affitech A/S. In 2016, ExpreS2ion Biotech Holding AB as founded.

History of ExpreS2ion


Year Event
2010 ExpreS2ion Biotechologies ApS is founded.
2010 The company receives investment of 6.5 MDKK (cirka 8 MSEK)
2010 First customer contract signed
2011 ExpreS2ion was selected by the Accelerace board as a very promising start-up company
2011 The company receives a HTF grant worth 3.5 MDKK (~4 MDKK) together with University of Copenhagen and CMC Biologics for malaria research.
2012 The company signs the first research licenses with two major pharmaceutical companies
2012 The company receives a Eurostars grant for the optimisation of the S2 cell line, in cooperation with malaria research at University of Copenhagen and Mucosis
2012 Received a major EU grant (FP7) in the malaria vaccine call together with EVI (European Vaccine Initiative, Heidelberg, IRD (Institut de Recherche pour le Dévelopement, Paris) and UAC (Université d’Abomey-Calavi, Benin).
2013 The Company’s application for trademark protection for “ExpreS2ion” approved.
2013 The Company’s patent application is approved in Japan
2013 Jenner Institute at the University of Oxford receives MRC and EVI contributions for preclinical development RH5 vaccine, developed on the ExpreS2 platform together with the Company.
2013 ExpreS2ion Biotechnologies was appointed «Nordic Star» for Denmark at Nordic Life Science days
2013 The Company receives its first grant from PATH MVI with Jenner Institute for malaria research.
2014 First GMP (Good Manufacturing Practice) – production batch of proteins for P1 studies for malaria released.
2014 The ExpreS2 system was presented at three different regulatory authorities with no comments.
2014 A production run for toxicity studies of a malaria vaccine was produced at the Clinical BioManufacturing Facility at Oxford University, using a cell bank developed at The Company.
2014 Multi year research license signed with a big pharma company
2014 A scientific article, partly authored by researchers of the Company, was published in the journal Nature
2015 A second GMP-grade master cell bank is established for a customer.
2015 The Company raises funding of a total of 3.5 DKK (about 4 million), from existing shareholders including the Company’s founders and from new Swedish investors, through a rights issue.
2015 The Swedish parent company ExpreS2ion Biotech Holding AB is formed.
2015 The Company’s patent application in Denmark and China is approved.
2015 Trademark granted in USA
2015 The Company gets the final approval for a clinical phase Ia study in Germany.
2016 Customer projects established for the development of a vaccine against Zikavirus.
2016 The Company receives its second PATH grant.
2016 The Company co-authors an article published in the Journal of Nanobiotechnology
2016 Steen Klysner was hired as CEO and a new management team for the company was established.